Royalty Report: Drugs, Diagnostic, Disease – Collection: 203289

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Disease
  • Therapeutic
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203289

License Grant
Licensor grants to Licensee, in the Territory in the Field and during the Term, the non-transferable, exclusive right and license or sublicense under the Licensor Trademarks and Patents to Promote and Detail Zileuton IR and Zileuton XR, as applicable, together with Licensor and its Affiliates.
License Property
Trademarks means the ZYFLO(R) trademark and domain names.

The technology is Zileuton XR, the extended-release tablet formulation of Zileuton as described in Licensors NDA filed thereon; and  Zileuton IR,(the product), the immediate-release tablet formulation of Zileuton marketed as ZVFLO®, zileuton tablets, as described in the supplemental NDA relating thereto filed by Licensor.  Zileuton means the racemic compound 00-1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea.

Zileuton is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma.

Field of Use
Field shall mean the use as a pharmaceutical product in humans for asthma or other respiratory indications for which Licensor has received FDA approval, except for the Excluded Field.  The Excluded Field means the research, diagnostics, therapeutics and services related to the following to humans aged seven (7) years and under for intravenous or buccal administration of Zileuton and cardiovascular and vascular devices, including, without limitation, stents.

IPSCIO Record ID: 203507

License Grant
Licensor grants an exclusive license under the Patents and Know How to develop, have developed, make, have made, use, have used, import, have imported, offer to sell, sell, and have sold the Product in the Territory.

Licensor grants, subject to third partys written consent, an exclusive sublicense under Licensors rights to Patents and Know How pursuant to the License Agreement to develop, have developed, make, have made, use, have used, import, have imported, offer to sell, sell, and have sold Zileuton CR in the Field in the Territory.

License Property
The Product is any pharmaceutical product which incorporates the Compound, including without limitation Zileuton CR and Zileuton IV, but excluding the Excluded Product.

The Compound is Zileuton.  Zileuton CR is the controlled release formulation of the Compound.  Zileuton IV is the intravenous formulation of the Compound.  The Excluded Product is the finished form of the Compound currently marketed under the trade name of Zyflo.

Zileuton (trade name ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma.

Field of Use
The Field shall mean research, diagnostics, therapeutics, and services for all human medical conditions or diseases, except for research, diagnostics, therapeutics, and services related to the following Excluded Pediatrics, cardiovascular and vascular devices, including, without limitation, stents, and Excluded Product.

'Indication' shall mean a distinct disease or condition in the Field for which Regulatory Approval has been sought and/or obtained, including, without limitation, all forms of the following diseases or conditions asthma, chronic obstructive pulmonary disease, and emphysema.

IPSCIO Record ID: 203372

License Grant
Licensor grants an exclusive license under the Patents and Know How to develop, have developed, make, have made, use, have used, import, have imported, offer to sell, sell, and have sold the Product in the Territory for use in the Field.

Licensor irrevocably and unconditionally sells, transfers, conveys, assigns and delivers, and Licensee hereby purchases all right, title and interest in and to the Trademark and the goodwill.

License Property
The trademark shall mean the mark ZYFLO.

The Product is any pharmaceutical product which incorporates Zyflo or an immediate release formulation of the compound Zileuton.

Zileuton (trade name ZYFLO) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma.

Field of Use
The Field shall mean research, diagnostics, therapeutics, and services for all human medical conditions or diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.